• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于胸腔积液的列线图预测未经选择的多发性骨髓瘤患者的预后:一项大型单中心经验。

Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.

作者信息

Hou Zi-Liang, Kang Yu, Yang Guang-Zhong, Wang Zhen, Wang Feng, Yu Yan-Xia, Chen Wen-Ming, Shi Huan-Zhong

机构信息

Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.

Department of Respiratory and Critical Care Medicine, Beijing Luhe Hospital, Capital Medical University, Beijing, 101100, China.

出版信息

Ann Hematol. 2021 Jul;100(7):1789-1801. doi: 10.1007/s00277-021-04484-1. Epub 2021 Mar 14.

DOI:10.1007/s00277-021-04484-1
PMID:33715037
Abstract

Pleural effusion (PE) is prevalent in unselected "real-life" populations of multiple myeloma (MM). However, its prognostic value on MM is currently elusive. This study aimed to explore the role of PE on MM prognosis and to develop a novel prognostic nomogram for a cohort of Chinese patients with MM. Patients diagnosed with MM form 2000 through 2017 were retrospectively enrolled. PE was evaluated by chest computed tomography (CT) scans. Independent predictors of overall survival (OS) were identified using a multivariable Cox regression model performed on variables selected by the least absolute shrinkage and selection operator (LASSO) algorithm. A nomogram was constructed based on these variables. The concordance index (C-index) and the calibration curve were used to evaluate the predictive performance of the nomogram. Among 861 patients analyzed, 368 patients developed PE. Multivariate cox regression and restricted mean survival time (RMST) analyses revealed that patients with PE experienced worse OS vs. patients without PE. A nomogram predictive of OS was constructed using PE, plasma cell proportion, international staging system (ISS) stage, Charlson comorbidity index (CCI), 1q21 gain, and autologous hematopoietic stem cell transplantation (HSCT). The nomogram showed satisfactory discrimination in the derivation cohort (C-index=0.729) and the validation cohort (C-index=0.684), outperforming the Durie-Salmon (DS) and ISS staging systems. Moreover, the nomogram accurately classified patients into two distinct high- and low-risk groups. PE is frequently encountered in the disease course for MM patients. We derivated and validated a novel nomogram for MM based on PE, outperforming the DS/ISS staging systems.

摘要

胸腔积液(PE)在未经过挑选的多发性骨髓瘤(MM)“真实世界”人群中很常见。然而,其对MM的预后价值目前尚不清楚。本研究旨在探讨PE在MM预后中的作用,并为一组中国MM患者开发一种新的预后列线图。回顾性纳入了2000年至2017年诊断为MM的患者。通过胸部计算机断层扫描(CT)评估PE。使用基于最小绝对收缩和选择算子(LASSO)算法选择的变量进行多变量Cox回归模型来确定总生存期(OS)的独立预测因素。基于这些变量构建列线图。一致性指数(C指数)和校准曲线用于评估列线图的预测性能。在分析的861例患者中,368例患者发生了PE。多变量Cox回归和受限平均生存时间(RMST)分析显示,与无PE的患者相比,有PE的患者OS更差。使用PE、浆细胞比例、国际分期系统(ISS)分期、Charlson合并症指数(CCI)、1q21增益和自体造血干细胞移植(HSCT)构建了预测OS的列线图。该列线图在推导队列(C指数=0.729)和验证队列(C指数=0.684)中显示出令人满意的区分度,优于Durie-Salmon(DS)和ISS分期系统。此外,列线图准确地将患者分为两个不同的高风险和低风险组。MM患者在病程中经常出现PE。我们基于PE推导并验证了一种新的MM列线图,其性能优于DS/ISS分期系统。

相似文献

1
Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.基于胸腔积液的列线图预测未经选择的多发性骨髓瘤患者的预后:一项大型单中心经验。
Ann Hematol. 2021 Jul;100(7):1789-1801. doi: 10.1007/s00277-021-04484-1. Epub 2021 Mar 14.
2
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.新型药物时代自体造血干细胞移植后多发性骨髓瘤早期复发的预后列线图。
Cancer Med. 2023 Apr;12(8):9085-9096. doi: 10.1002/cam4.5630. Epub 2023 Apr 6.
3
Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.纳入细胞因子的预后列线图用于预测初诊多发性骨髓瘤患者的总生存。
Int Immunopharmacol. 2021 Oct;99:108016. doi: 10.1016/j.intimp.2021.108016. Epub 2021 Aug 9.
4
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.硼替佐米为基础的诱导治疗、大剂量化疗和自体造血干细胞移植治疗多发性骨髓瘤患者的定量综合生存预测。
JCO Precis Oncol. 2024 Jul;8:e2300613. doi: 10.1200/PO.23.00613.
5
Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma.用于新诊断多发性骨髓瘤患者总体生存的预后列线图。
Biomed Res Int. 2019 Apr 8;2019:5652935. doi: 10.1155/2019/5652935. eCollection 2019.
6
Development and Validation of a Nomogram-Based Prognostic Evaluation Model for Sarcomatoid Hepatocellular Carcinoma.肉瘤样肝细胞癌列线图预后评估模型的建立与验证。
Adv Ther. 2020 Jul;37(7):3185-3205. doi: 10.1007/s12325-020-01357-3. Epub 2020 May 20.
7
Development and validation of a prognostic nomogram for malignant esophageal fistula based on radiomics and clinical factors.基于影像组学和临床因素的恶性食管瘘预后列线图的建立和验证。
Thorac Cancer. 2021 Dec;12(23):3110-3120. doi: 10.1111/1759-7714.14115. Epub 2021 Oct 14.
8
Pleural Effusion in Multiple Myeloma.多发性骨髓瘤中的胸腔积液
Intern Med. 2016;55(4):339-45. doi: 10.2169/internalmedicine.55.4733. Epub 2016 Feb 15.
9
Pre-transplant CRP-albumin ratio as a biomarker in patients receiving haploidentical allogeneic hematopoietic transplantation: Developing a novel DRCI-based nomogram.移植前 C 反应蛋白-白蛋白比值作为接受单倍体相合异基因造血移植患者的生物标志物:建立一种基于 DRCI 的新的列线图。
Front Immunol. 2023 Feb 15;14:1128982. doi: 10.3389/fimmu.2023.1128982. eCollection 2023.
10
Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma.局部晚期鼻咽癌预后列线图
Sci Rep. 2020 Jan 21;10(1):861. doi: 10.1038/s41598-020-57968-x.

引用本文的文献

1
Correlation between initial alkaline phosphatase levels and overall survival in newly diagnosed multiple myeloma patients.新诊断的多发性骨髓瘤患者初始碱性磷酸酶水平与总生存期的相关性。
Transl Cancer Res. 2024 Jul 31;13(7):3328-3337. doi: 10.21037/tcr-24-330. Epub 2024 Jul 23.
2
Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.哪些因素与多发性骨髓瘤患者手术后的不良预后相关?——列线图的初步建立与验证。
World J Surg Oncol. 2024 Jun 25;22(1):168. doi: 10.1186/s12957-024-03453-y.
3
Mitophagy-related gene signature for predicting the prognosis of multiple myeloma.

本文引用的文献

1
Development of a prognostic model for overall survival in multiple myeloma using the Connect MM Patient Registry.利用 Connect MM 患者注册中心开发多发性骨髓瘤总生存预后模型。
Br J Haematol. 2019 Dec;187(5):602-614. doi: 10.1111/bjh.16139. Epub 2019 Aug 5.
2
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.多发性骨髓瘤患者细胞遗传学预后指数的建立与验证:对生存的预测作用。
J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.
3
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.
用于预测多发性骨髓瘤预后的线粒体自噬相关基因特征
Heliyon. 2024 Jan 13;10(3):e24520. doi: 10.1016/j.heliyon.2024.e24520. eCollection 2024 Feb 15.
4
Integration of clinical features and sociodemographic factors: a simplified prognostic model for patients with multiple myeloma based on a double-center retrospective analysis.临床特征与社会人口学因素的整合:基于双中心回顾性分析的多发性骨髓瘤患者简化预后模型
Am J Cancer Res. 2023 Mar 15;13(3):1038-1048. eCollection 2023.
5
Development and validation a simple scoring system to identify malignant pericardial effusion.开发并验证一种用于识别恶性心包积液的简单评分系统。
Front Oncol. 2022 Dec 1;12:1012664. doi: 10.3389/fonc.2022.1012664. eCollection 2022.
6
Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification.临床列线图在多发性骨髓瘤患者总生存和无事件生存预测中的应用:预后分层的可视化工具。
Front Public Health. 2022 Oct 17;10:958325. doi: 10.3389/fpubh.2022.958325. eCollection 2022.
7
Predicting the risk of acute kidney injury after hematopoietic stem cell transplantation: development of a new predictive nomogram.预测造血干细胞移植后急性肾损伤的风险:新预测列线图的制定。
Sci Rep. 2022 Sep 12;12(1):15316. doi: 10.1038/s41598-022-19059-x.
8
Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities.整合肿瘤负荷和合并症的新诊断多发性骨髓瘤总生存新型预后模型的开发与验证
Front Oncol. 2022 Mar 17;12:805702. doi: 10.3389/fonc.2022.805702. eCollection 2022.
不适于移植的骨髓瘤患者结局及治疗方案的临床预测模型(英国骨髓瘤研究联盟风险评估):一项开发与验证研究
Lancet Haematol. 2019 Mar;6(3):e154-e166. doi: 10.1016/S2352-3026(18)30220-5. Epub 2019 Feb 6.
4
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
5
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.新诊断多发性骨髓瘤患者随机对照试验的常见纳入标准分析及结果推断
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2. doi: 10.1016/j.clml.2017.06.013. Epub 2017 Jun 17.
6
Pleural Effusion in Multiple Myeloma: Characteristics and Practice Patterns.多发性骨髓瘤中的胸腔积液:特征与实践模式
Acta Haematol. 2017;138(2):69-76. doi: 10.1159/000477793. Epub 2017 Aug 11.
7
Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.t(4;14)、del(17p13)、del(1p32)和1q21获得性荧光原位杂交探针的联合使用可识别克隆异质性,并提高233例新诊断多发性骨髓瘤中不良细胞遗传学特征的检测率。
Mol Cytogenet. 2017 Jul 1;10:26. doi: 10.1186/s13039-017-0327-3. eCollection 2017.
8
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.新诊断骨髓瘤的预后预测:1905 试验患者分子谱的荟萃分析。
Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.
9
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.在未经选择的多发性骨髓瘤患者独立队列中对修订的国际分期系统进行评估。
Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27.
10
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.来那度胺联合化疗与自体移植,随后来那度胺联合泼尼松与来那度胺维持治疗多发性骨髓瘤患者:一项随机、多中心、3 期试验。
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.